GR3004199T3 - - Google Patents

Info

Publication number
GR3004199T3
GR3004199T3 GR920400570T GR920400570T GR3004199T3 GR 3004199 T3 GR3004199 T3 GR 3004199T3 GR 920400570 T GR920400570 T GR 920400570T GR 920400570 T GR920400570 T GR 920400570T GR 3004199 T3 GR3004199 T3 GR 3004199T3
Authority
GR
Greece
Prior art keywords
cyclosporins
cyclodextrin
fungal
admixture
rendered
Prior art date
Application number
GR920400570T
Other languages
Greek (el)
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GR3004199T3 publication Critical patent/GR3004199T3/el

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GR920400570T 1987-06-04 1992-03-31 GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14070387 1987-06-04

Publications (1)

Publication Number Publication Date
GR3004199T3 true GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-03-31

Family

ID=15274767

Family Applications (1)

Application Number Title Priority Date Filing Date
GR920400570T GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1987-06-04 1992-03-31

Country Status (10)

Country Link
US (1) US5051402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0294239B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2577049B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE72629T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU607506B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1325973C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3868438D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2033429T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK28097A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
JPH07111785B2 (ja) 1990-01-19 1995-11-29 富士通株式会社 光ディスク
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
FR2670629B1 (fr) * 1990-12-17 1995-03-10 Moving Magnet Tech Actionneur electromagnetique monophase rotatif.
DE69222150T2 (de) * 1991-01-25 1998-01-15 Fujisawa Pharmaceutical Co Prozess zur produktion von cyclosporin-a und/oder c
WO1993023010A1 (en) * 1992-05-13 1993-11-25 Sandoz Ltd. Ophthalmic compositions containing a cyclosporin
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
NZ247516A (en) * 1993-04-28 1995-02-24 Bernard Charles Sherman Water dispersible pharmaceutical compositions comprising drug dissolved in solvent system comprising at least one alcohol and at least one surfactant
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
AU2577295A (en) * 1994-06-01 1995-12-21 Yuhan Corporation Cyclosporin containing composition and process for the preparation thereof
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
JP2007056045A (ja) * 1995-05-26 2007-03-08 Nobaruteisu Fuaama Kk サイクロデキストリン組成物
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
HUP0001013A3 (en) 1997-01-30 2004-10-28 Novartis Ag Oil-free pharmaceutical compositions containing cyclosporin a
NZ328751A (en) 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
ATE423130T1 (de) 1997-10-08 2009-03-15 Isotechnika Inc Deuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agenzien
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
JP2002523475A (ja) * 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DK1714977T3 (da) 2001-10-19 2009-07-06 Isotechnika Inc Syntese af cyclosporinanaloger
MXPA04003623A (es) * 2001-10-19 2004-12-02 Isotechnika Inc Nuevas formulaciones analogas de ciclosporina.
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
EP1689390B1 (en) 2003-11-21 2011-02-09 Zalicus Inc. Methods and reagents for the treatment of inflammatory disorders
US7691812B2 (en) 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
PL1904056T3 (pl) 2005-07-18 2009-09-30 Minu Llc Zastosowanie makrolidu do przywracania czucia rogówkowego
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
FI118537B (fi) * 2006-03-08 2007-12-14 Kuopion Yliopisto Menetelmä syklodekstriinin kompleksoitumisen lisäämiseksi
AU2016203191B2 (en) * 2006-07-25 2018-03-01 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
WO2009048929A1 (en) 2007-10-08 2009-04-16 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mtor inhibitors
US20100016219A1 (en) * 2008-07-19 2010-01-21 Jerry Zhang Ophthalmic compositions containing solubilized cyclosporin
EP2440185B1 (en) 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
ES2780182T3 (es) * 2011-06-29 2020-08-24 Allergan Inc Formulaciones de 15-hidroxiestearato de macrogol
EA201792674A1 (ru) * 2015-05-29 2018-04-30 Окулис Эхф. Способ образования наночастиц циклоспорина а/циклодекстрина
CN105997863B (zh) * 2016-07-21 2018-09-04 河南省眼科研究所 环孢素a滴眼液及其制备方法
UA124774C2 (uk) 2016-11-29 2021-11-17 Окьюліс Са Приготування твердих циклодекстринових комплексів для доставки офтальмологічних активних фармацевтичних інгредієнтів
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3993807A1 (en) 2019-07-01 2022-05-11 Oculis SA Method for stabilizing the ph of an aqueous composition comprising a drug
CN112724200B (zh) * 2019-10-28 2022-09-27 上海云泽生物科技有限公司 一种稳定环孢霉素a的稀释液及其应用
EP4241761A4 (en) 2020-11-09 2024-09-25 Scai Therapeutics Co., Ltd. CYCLOSPORINE A SOLID AND DISPERSION COMPOSITION COMPRISING SAME

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
PH19156A (en) * 1982-02-01 1986-01-15 Sandoz Ltd Dihydrocyclosporin d in the treatment of multiple sclerosis
EP0094157B1 (en) * 1982-04-30 1987-07-29 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its use
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3580717D1 (de) * 1984-08-02 1991-01-10 Sandoz Ag Pharmazeutische anwendung von (nva)2-cyclosporine.

Also Published As

Publication number Publication date
EP0294239B1 (en) 1992-02-19
ES2033429T3 (es) 1993-03-16
AU1738688A (en) 1988-12-22
US5051402A (en) 1991-09-24
HK28097A (en) 1997-03-06
ATE72629T1 (de) 1992-03-15
CA1325973C (en) 1994-01-11
AU607506B2 (en) 1991-03-07
JP2577049B2 (ja) 1997-01-29
JPS6485921A (en) 1989-03-30
DE3868438D1 (de) 1992-03-26
EP0294239A1 (en) 1988-12-07

Similar Documents

Publication Publication Date Title
GR3004199T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR3005454T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT1232243B (it) Composizioni farmaceutiche a base di ciclosporine
CA2076663A1 (en) Recessed Patellar Prosthesis
MY102660A (en) Therapeutic system for sparingly soluble active ingredients
MY101593A (en) Sustained release preparation.
GB8922026D0 (en) Novel anti-viral and cytotoxic agent
DE3882631D1 (de) Waessrige dispersionen.
DE58903472D1 (de) Implantierbarer injektionskoerper.
CA2004451A1 (en) Enossal implant
ES2065906T3 (es) Produccion de proteinas en formas activas.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
EP0827748A3 (en) Peritoneal dialysis solution
NO893826L (no) Fremgangsmaate for fremstilling av 2'-halomethyliden, 2'-ethenyliden og 2'-ethenyladenosinderivater.
EP0259982A3 (en) Solid iodophor composition
RU96114157A (ru) Способ лечения острых отравлений
DE3867086D1 (de) Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
GR3004303T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS6485990A (en) Antihypertestoeronemia agent
FR2572932B1 (fr) Medicament insoluble administre localement dans l'oreille
JPS6461429A (en) Remedy for cancer
TR26166A (tr) SUDA CÖZüLEBILEN FTALOSIYANIN 'LI BOYAR MADDELER, BUNLARIN üRETILMESINE MAHSUS USUL VE KULLANILMA- LARI.
PT968717E (pt) Preparacao sob a forma galenica simples visando limitar os efeitos ocorridos durante a menopausa, e posteriormente, e tratamento com esta preparacao
Libowitz Jews and Christians: The Contemporary Meeting
Hennesey Louis William DuBourg: Bishop of Louisiana and the Floridas, Bishop of Montauban and Archbishop of Besancon, 1766-1833